The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

Shimabukuro-Vornhagen,Alexander; Draube,Andreas; Liebig,Tanja; Popov,Alexey; Rothe,Achim; von Bergwelt-Baildon,Michael

doi:10.3892/or.2012.2215

The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2

Authors:
- Alexander Shimabukuro-Vornhagen
- Andreas Draube
- Tanja Liebig
- Alexey Popov
- Achim Rothe
- Michael von Bergwelt-Baildon
View Affiliations

Affiliations: Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, D-50924 Cologne, Germany
Published online on: December 28, 2012 https://doi.org/10.3892/or.2012.2215
Pages: 1061-1065

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor vaccination represents a promising immunotherapeutic strategy in cancer. However, the inherent ability of many tumors to evade immune responses by suppression of immune cell function represents a major barrier. Prostaglandin E2 (PGE2) has been shown to be a critical tumor-derived immunosuppressive factor. It affects a broad range of immune cells including T cells, macrophages and dendritic cells (DCs). CD40-activated B cells are being studied as a potential alternative to DCs as antigen-presenting cells for immunotherapy. So far, it is not known whether PGE2 affects their antigen presenting capacity. We, therefore, investigated the influence of PGE2 on the phenotype, migratory potential and antigen-presenting function of CD40-activated human B cells. Here, we demonstrate that the immunostimulatory properties of CD40-activated B cells are not affected by PGE2. These results support the use of CD40-activated B cells as cellular adjuvants, especially in settings where PGE2 is present in the tumor microenvironment.

View Figures

View References

1	Rosenberg S, Yang J and Restifo N: Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909–915. 2004. View Article : Google Scholar : PubMed/NCBI
2	Finn OJ: Cancer immunology. N Engl J Med. 358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
4	Palucka K, Ueno H and Banchereau J: Recent developments in cancer vaccines. J Immunol. 186:1325–1331. 2011. View Article : Google Scholar : PubMed/NCBI
5	Copier J, Dalgleish AG, Britten CM, et al: Improving the efficacy of cancer immunotherapy. Eur J Cancer. 45:1424–1431. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kalinski P: Regulation of immune responses by prostaglandin E₂. J Immunol. 188:21–28. 2012. View Article : Google Scholar : PubMed/NCBI
8	Matsuoka T and Narumiya S: The roles of prostanoids in infection and sickness behaviors. J Infect Chemother. 14:270–278. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sheng KC, Wright MD and Apostolopoulos V: Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem. 18:5507–5518. 2011. View Article : Google Scholar : PubMed/NCBI
10	Sombroek CC, Stam AG, Masterson AJ, et al: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 168:4333–4343. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kolenko V, Rayman P, Roy B, et al: Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood. 93:2308–2318. 1999.
12	Walker W and Rotondo D: Prostaglandin E₂ is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology. 111:298–305. 2004.
13	Obermajer N, Muthuswamy R, Lesnock J, et al: Positive feedback between PGE₂ and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 118:5498–5505. 2011.PubMed/NCBI
14	Krishnamoorthy S and Honn KV: Eicosanoids in tumor progression and metastasis. Subcell Biochem. 49:145–168. 2008. View Article : Google Scholar : PubMed/NCBI
15	Haas AR, Sun J, Vachani A, et al: Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res. 12:214–222. 2006. View Article : Google Scholar : PubMed/NCBI
16	Luft T, Jefford M, Luetjens P, et al: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 100:1362–1372. 2002. View Article : Google Scholar : PubMed/NCBI
17	Scandella E, Men Y, Gillessen S, et al: Prostaglandin E₂ is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 100:1354–1361. 2002.
18	Braun D, Longman RS and Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 106:2375–2381. 2005. View Article : Google Scholar : PubMed/NCBI
19	Von Bergwelt-Baildon MS, Popov A, Saric T, et al: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E₂ and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 108:228–237. 2006.PubMed/NCBI
20	Muthuswamy R, Mueller-Berghaus J, Haberkorn U, et al: PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood. 116:1454–1459. 2010. View Article : Google Scholar : PubMed/NCBI
21	Martin F and Chan AC: B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 24:467–496. 2006. View Article : Google Scholar : PubMed/NCBI
22	Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al: The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 114:4919–4927. 2009. View Article : Google Scholar : PubMed/NCBI
23	Mason NJ, Coughlin CM, Overley B, et al: RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 15:955–965. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sorenmo KU, Krick E, Coughlin CM, et al: CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS One. 6:e241672011.PubMed/NCBI
25	Von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al: CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 107:2786–2789. 2006.PubMed/NCBI
26	Wiesner M, Zentz C, Mayr C, et al: Conditional immortalization of human B cells by CD40 ligation. PLoS One. 3:e14642008. View Article : Google Scholar : PubMed/NCBI
27	Kondo E, Gryschok L, Klein-Gonzalez N, et al: CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 155:249–256. 2009. View Article : Google Scholar : PubMed/NCBI
28	Liebig TM, Fiedler A, Zoghi S, et al: Generation of human CD40-activated B cells. J Vis Exp. pii. 13732009.PubMed/NCBI
29	Popov A, Driesen J, Abdullah Z, et al: Infection of myeloid dendritic cells with Listeria monocytogenes leads to the suppression of T cell function by multiple inhibitory mechanisms. J Immunol. 181:4976–4988. 2008.PubMed/NCBI
30	Chemnitz JM, Driesen J, Classen S, et al: Prostaglandin E₂ impairs CD4⁺ T cell activation by inhibition of lck: implications in Hodgkin’s lymphoma. Cancer Res. 66:1114–1122. 2006.
31	Bekeredjian-Ding I, Schafer M, Hartmann E, et al: Tumour-derived prostaglandin E₂ and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology. 128:439–450. 2009.
32	Herfs M, Herman L, Hubert P, et al: High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother. 58:603–614. 2009. View Article : Google Scholar : PubMed/NCBI
33	Muthuswamy R, Urban J, Lee JJ, et al: Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68:5972–5978. 2008. View Article : Google Scholar : PubMed/NCBI
34	Krause P, Singer E, Darley PI, et al: Prostaglandin E₂ is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol. 82:1106–1114. 2007.
35	Wobser M, Voigt H, Houben R, et al: Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother. 56:1017–1024. 2007. View Article : Google Scholar : PubMed/NCBI
36	Forster R, Schubel A, Breitfeld D, et al: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 99:23–33. 1999. View Article : Google Scholar : PubMed/NCBI
37	Ohl L, Mohaupt M, Czeloth N, et al: CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 21:279–288. 2004. View Article : Google Scholar : PubMed/NCBI
38	Kabashima K, Shiraishi N, Sugita K, et al: CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol. 171:1249–1257. 2007. View Article : Google Scholar : PubMed/NCBI
39	Schultze JL, Grabbe S and von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25:659–664. 2004. View Article : Google Scholar : PubMed/NCBI
40	Kim SK, Nguyen Pham TN, Nguyen Hoang TM, et al: Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 88:1113–1123. 2009. View Article : Google Scholar : PubMed/NCBI
41	Harizi H, Grosset C and Gualde N: Prostaglandin E₂ modulates dendritic cell function via EP₂ and EP₄ receptor subtypes. J Leukoc Biol. 73:756–763. 2003.
42	Legler DF, Krause P, Scandella E, et al: Prostaglandin E₂ is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 176:966–973. 2006.PubMed/NCBI
43	Fedyk ER and Phipps RP: Prostaglandin E₂ receptors of the EP₂ and EP₄ subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA. 93:10978–10983. 1996.PubMed/NCBI
44	Lee H, Trott JS, Haque S, et al: A cyclooxygenase-2/prostaglandin E₂ pathway augments activation-induced cytosine deaminase expression within replicating human B cells. J Immunol. 185:5300–5314. 2010.PubMed/NCBI